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The myelodysplastic syndromes (MDS) are a group of clonal hematopoietic disorders 
characterized by ineffective hematopoiesis resulting in cytopenias and an increased risk 
of transformation to acute myeloid leukemia.  Currently, the only curative therapy for 
MDS is an allogeneic hematopoietic stem cell transplantation (HSCT); however, old 
age and other comorbidities limit tolerability of conditioning regimens for HSCT, 
offsetting its benefits for patients. Among a wide range of genetic and epigenetic 
aberrations associated with MDS pathogenesis, dysregulation of ribosome biogenesis 
has been implicated. Using the Vav-cre-Asxl1-Tet2 mouse model of MDS, we show 
that delivering a ribosomal inactivating protein, saporin, via the internalization of the 
CD117 receptor, results in the depletion of normal and malignant stem cells with 
minimal effects on bone marrow cellularity.  Furthermore, we show that the depletion 
of malignant cells allows for sufficient engraftment of healthy stem cells into recipient 
mice. Together, these studies demonstrate that CD117-saporin treatment leads to the 
depletion of malignant stem cells and can serve as a conditioning regimen for HSCT 
opening a potential therapeutic window for MDS treatment.  
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CHAPTER ONE 
INTRODUCTION 
 
CLINICAL FEATURES OF THE MYELODYSPLASTIC SYNDROMES  
 
The myelodysplastic syndromes are a collection of chronic malignancies with unique 
clinical manifestations and prognoses. Identification and classification of MDS and 
other blood malignancies was only made possible after accurate enumeration and 
visual characterization of blood and bone marrow cells were made possible. Early 
tools, such as the light microscope, hemocytometers, and tissue staining methods, 
provided insights into the connection between disease and blood cells by providing 
quantitative and qualitative measures to correlate with disease symptoms. More 
recently, advent of flow cytometry and sequencing technologies have provided a 
deeper molecular understanding of disease biology.  
 
Early observations found a link between anemia, BM failure, and leukemia resulting 
in MDS being described as a preleukemic condition. It wasn’t until a study in 1970 
showing patients with high blast counts at the time of diagnosis progressed to 
leukemia more so than patients with lower blast counts that raised the possibility for 
MDS being an independent malignancy (Najean and Pecking 2008). It was also noted 
that some patients with preleukemia never developed leukemia and the term 
myelodysplasia was proposed (William B. Fisher, MD; Steven A. Armentrout, MD; 
Russell Weisman Jr. 1973). It wasn’t for another decade that a definitive classification 
was published and accepted. In 1982, the French American British (FAB) Group 
reported five subtypes of MDS diagnosed by blast percentage and ring sideroblasts (J. 
M. Bennett D. Catovsky M. T. Daniel G. Flandrin D. A. G. Galton H. R. Gralnick C. 
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Sultan 1982). Since then, FAB and the World Health Organization (WHO) have been 
updating the recommendations for diagnosis.  
 
Epidemiology 
It wasn’t until 2001 that MDS cases became reportable to the National Cancer 
Institute’s Survey, Epidemiology and End Results (SEER) cancer database. From the 
data collected, it is estimated that MDS occurs in 4.9 individuals per 100,000, 13.5 per 
100,000 in patients 65 years and older (Cogle 2015).  With a median age of 76 years at 
diagnosis, age is a major risk factor in the development of the disease (Figure 1.1) 
(Ma et al. 2007; Xiaomei 2012). Despite advances in understanding disease 
pathogenesis, no significant improvement in survival rates have been observed in the 
past decade (Mayer et al. 2017). Furthermore, as awareness of reporting criteria 
increases and as the population ages, the number of MDS patients is likely to increase 
in the coming decades making the need for new therapies even more critical.  
 
Figure 1.1.  Incidence Rate of Myelodysplastic Syndromes (MDS) in Different Age 
Groups in the United States (2001 to 2008).  Adapted from Xiaomei, 2012. 
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Diagnosis & Classification 
MDS is first suspected after an abnormal complete blood count (CBC) or a blood 
smear show cytopenias. Once nonmalignant causes of the cytopenias are excluded, the 
BM is assessed for cellularity, dysplasia, presence of blasts, and cytogenic and 
mutational profiles are analyzed and based on the current WHO recommendations, the 
disease is subcategorized as MDS with single lineage dysplasia, MDS with 
multilineage dysplasia, MDS with ring sideroblasts with single lineage dysplasia, 
MDS with ring sideroblasts with multilineage dysplasia, MDS with isolated del5q, 
MDS with excess blasts 1, MDS with excess blasts 2, or unclassified MDS (Table 
1.1) (Arber et al. 2016).  In addition to these subtypes, MDS can be classified as 
primary or secondary. Primary MDS, or de novo MDS, is the more common type and 
no clear risk factors are known. Secondary MDS, also known as therapy-related MDS 
(t-MDS), generally occurs as a result of DNA damage from chemotherapy or 
radiation. (Cutler, 2014) 
 
According to the International Prognostic Scoring System (IPSS-R) prognostic factors 
for MDS include cytopenia, blast percentage, cytogenetic abnormalities, fibrosis, and 
more recently, genetic mutations flow cytometry analysis of BM. Using these 
prognostic factors MDS is categorized into high-risk and low-risk. 
Lower-risk (IPSS score ≤1.0) MDS patients primarily suffer from BM 
hypercellularity and peripheral cytopenia resulting from a significantly increased  
rate of apoptosis among BM hematopoietic cells. In contrast, BM hematopoietic 
cells in higher-risk MDS patients demonstrate resistance to apoptosis, and some of  
these patients subsequently develop AML (Greenberg 1998; Y. Yoshida, Anzai, 
and Kawabata 1995).  
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Table 1.1: WHO Classification of MDS Subtypes ↵* Cytopenias defined as: hemoglobin, <10 g/dL; platelet count, <100 × 109/L; and 
absolute neutrophil count, <1.8 × 109/L. Rarely, MDS may present with mild anemia or 
thrombocytopenia above these levels. PB monocytes must be <1 × 109/L ↵† If SF3B1 mutation is present. ↵‡ One percent PB blasts must be recorded on at least 2 separate occasions. ↵§ Cases with ≥15% ring sideroblasts by definition have significant erythroid dysplasia, 
and are classified as MDS-RS-SLD. 
 
   Name Dysplastic lineages Cytopenias
* Ring Sideroblasts 
BM and PB 
blasts Cytogenetics  
MDS with single 
lineage dysplasia  1 1 or 2 <15%/<5%
† 
BM <5%, PB 
<1%, no Auer 
rods 
Any, unless fulfills all criteria for MDS 
with isolated del(5q) 
MDS with 
multilineage 
dysplasia 
2 or 3 1-3 <15%/<5%† 
BM <5%, PB 
<1%, no Auer 
rods 
Any, unless fulfills all criteria for MDS 
with isolated del(5q) 
MDS with ring 
sideroblasts 
     
MDS-RS with 
single lineage   
dysplasia 
1 1 or 2 ≥15%/≥5%† 
BM <5%, PB 
<1%, no Auer 
rods 
Any, unless fulfills all criteria for MDS 
with isolated del(5q) 
MDS-RS with 
multilineage     
dysplasia 
2 or 3 1-3 ≥15%/≥5%† 
BM <5%, PB 
<1%, no Auer 
rods 
Any, unless fulfills all criteria for MDS 
with isolated del(5q) 
MDS with isolated 
del(5q) 1-3 1-2 None or any 
BM <5%, PB 
<1%, no Auer 
rods 
del(5q) alone or with 1 additional 
abnormality except −7 or del(7q) 
MDS with excess 
blasts 
     
MDS-EB-1 0-3 1-3 None or any 
BM 5%-9% or 
PB 2%-4%, no 
Auer rods 
Any 
MDS-EB-2 0-3 1-3 None or any 
BM 10%-19% 
or PB 5%-19% 
or Auer rods 
Any 
MDS, 
unclassifiable 
     
with 1% blood 
blasts 1-3 1-3 None or any 
BM <5%, PB = 
1%,‡ no Auer 
rods 
Any 
with single lineage 
dysplasia and     
pancytopenia 
1 3 None or any 
BM <5%, PB 
<1%, no Auer 
rods 
Any 
based on defining 
cytogenetic  
 abnormality 
0 1-3 <15%§ 
BM <5%, PB 
<1%, no Auer 
rods 
MDS-defining abnormality 
 Refractory 
cytopenia of     
Childhood  
1-3 1-3 None BM <5%, PB <2% Any 
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As high-risk patients exhibit short survival and are more likely to progress to AML, 
more aggressive therapy, including hematopoietic stem cell transplantation (HSCT) 
is recommended with the aim to modify the course of the disease. Currently, HSCT 
is the only curative therapy for MDS; however, old age and other comorbidities limit 
tolerability of conditioning regimens for HSCT, offsetting its benefits for patients.  
Other therapies for high-risk patients include hypomethylating agents, azacytidine 
and decitabine (Cutler 2014). Low-risk MDS patients are treated with growth factors 
(EPO stimulating agents, G-CSF) and immunomodularory agents (antithymocyte, 
globulin, or lenalinomide) (Pierre Fenaux and Lionel Ad `es 2013). Over the last few 
years, better understanding of the disease biology has let to novel targets for therapy. 
Luspatercept, is a fusion protein that blocks transforming growth factor beta (TGF-B) 
alleviating the block in erythropoiesis in low-risk MDS patients (Platzbecker et al. 
2017). Currently, phase III trials are evaluating efficacy, and if successful, 
Luspatercept will become the third drug to be approved by the FDA for MDS 
(Giagounidis 2018).  
 
THE CELL OF ORIGIN 
 
Identification Murine HSCs 
MDS is a thought to be a clonal disorder originating in HSCs (Sperling, Gibson, and 
Ebert 2017; Woll et al. 2014). To better understand the pathogenesis of MDS, it is 
important to understand the defining features of HSCs.  
 
19th century scientist, Franz Ernst Christian Neumann, was the first to propose the 
theory that all cell lineages in the blood originate from one cell. Early evidence of the 
HSCs came in a surprising finding when a group studying methods of recovery from 
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radiation injury observed that transplanting normal mouse BM protected recipient 
mice from lethal dose of radiation giving them a new source of blood cell lineages 
(Jacobson et al. 1951,Ford et al. 1956). More direct evidence of HSCs was proposed 
when Till and McCulloch performed transplantation of BM cells into irradiated mice 
and used x-ray induced lineage tracking to observe colony formation in the spleen. 
They showed that the number of cells transplanted was proportional to the number of 
colonies observed (Becker, McCulloch, and Till 1963; Till and McCulloch 1961).  
Moreover, these colonies distinct from one another, indicating multilineage potential 
of the transplanted cells (Becker et al. 1963). In 1957, E. Donnall Thomas performed 
the first successful stem cell transplantation demonstrating that injecting BM cells can 
lead to long-term repopulation of blood cells (E. Donnall Thomas, M.D.†, Harry L. 
Lochte, Jr., M.D.‡, Wan Ching Lu, Ph.D.§, and Joseph W. Ferrebee 1957). Since then, 
such transplants were being performed however, the true identity of the HSC was still 
unknown.  It was these early studies that inspired the decades long exploration 
isolation and characterization of HSCs.  
 
Prospective separation of HSCs based on differential expression of cell surface 
markers became possible with the advent of fluorescence-based cell sorting making 
possible the enrichment of the HSC population. The Weissman group designed a 
strategy to purify HSCs using known cell surface markers for positive and negative 
selection. Using B220-, Gr-1-, Mac-1-, CD4-, CD8-, CD90lo, and Sca-1+, isolation of a 
multipotent HSC was made possible (GJ Spangrude, S Heimfeld 1988). In the 
following years, many groups identified additional cell surface markers by single-cell 
transplants to further define the hematopoietic hierarchy and to further purify the HSC 
population (Figure 1.2) (Benveniste et al. 2003; Ema et al. 2005; Kent et al. 2008; 
Kiel et al. 2005; Morrison and Weissman 1994; Osawa et al. 1996).  From these 
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studies, a purified murine HSC population can be obtained using Lin-, Sca-1+, cKit+, 
CD150+, CD34-, and CD48- combination staining.   
 
 
 
Figure 1.2. The Classical and Revised Roadmaps of Hematopoietic Hierarchy. (A) In 
the classical hierarchy roadmap, LT-HSCs and ST-HSCs are both multipotent but sit at 
different hierarchical levels owing to their distinct self-renewal abilities. The HSCs give 
rise to the MPPs with an accompanying reduction of self-renewal ability. Next there 
emerges a myeloid/lymphoid lineage segregation downstream of MPP. CLPs can produce 
lymphocytes. CMPs diverges into MEPs and GMPs. MEPs yield megakaryocytes and 
erythrocytes. GMPs generate granulocytes, macrophages, and dendritic cells. (B) In the 
revised hierarchy roadmap, LT-HSCs, IT-HSCs, and ST-HSCs/MPP1 cells are all 
multipotent but differ in their self-renewal ability. In the branching trees, the HSCs 
differentiate into MPPs, which consist of MPP2, MPP3, and MPP4/LMPP subpopulations. 
MPP2 and MPP3 cells mainly give rise to CMPs, whereas MPP4/LMPP cells 
predominantly generate lymphoid lineages. Next, CMPs can produce mature hematopoietic 
cells via MEP and GMP stages. CLPs can yield mature lymphocytes, which also can derive 
from MPP4/LMPP cells directly. Abbreviations: CLP, common lymphoid progenitor; CMP, 
common myeloid progenitor; GMP, granulocyte/macrophage progenitor; IT-HSC, 
intermediate-term hematopoietic stem cell; LMPP, lymphoid-primed multipotent 
progenitor; LT-HSC, long-term hematopoietic stem cell; MEP, megakaryocyte/erythrocyte 
progenitor; MPP, multipotent progenitor; ST-HSC, short-term hematopoietic stem cell. 
Reprinted from Zhang et al., 2018 
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Human HSC populations  
The advent of in vitro clonal assays and xenotransplatation models allowed for 
progress to be made in purifying the human HSCs population. An in vitro colony 
forming assay was established by growing human BM cells on agar for several weeks 
(Gartner and Kaplan 1980; Sutherland et al. 1989) allowing the ability to grow 
colonies from candidate HSC populations. Long-term repopulating assays were made 
possible by the breakthrough in humanized mouse models. Severe combined immune-
deficient (SCID) mice lacking T and B cells were used to engraft human BM cells 
(Kamel-Reid and Dick 1988; Lapidot et al. 1992). Success in this method provided a 
quantitative assay to measure long-term, multilineage potential of HSCs and gave a 
platform for the purification of human HSCs. The first cell surface marker found to 
enrich human HSCs was CD34 (Civin et al. 1984).  Further studies established CD90, 
CD38, and CD45RA as additional markers to purify HSCs (Baum et al. 1992; Bhatia 
et al. 1997; Conneally et al. 1997; Lansdorp, Sutherland, and Eaves 1990; Majeti, 
Park, and Weissman 2007; Murray et al. 1995). These studies not only isolated HSC-
rich populations, but also created an understanding of the hierarchy of the human 
hematopoietic system.  
 
 
Characteristics of HSCs 
Mature blood cells are generally short-lived and have to be replenished frequently to 
maintain normal peripheral blood counts. Residing in specialized niches in the BM, 
HSCs serve as a source of new blood cells by giving rise to terminally differentiated 
cells throughout the lifespan of an individual. This is made possible because HSCs 
maintain a balance of two key properties: differentiation and self-renewal.  The ability 
to differentiate allows the HSCs to give rise to mature cell types including 
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erythrocytes, monocytes, granulocytes, megakaryocytes, T and B lymphocytes, natural 
killer, and dendritic cells. This multipotent ability is the result of a hierarchical 
structure in which HSCs residing at the top, progressively differentiating into 
multipotent progenitors, followed by committed progenitors with restricted lineage 
potential which eventually give rise to mature cells. Another defining characteristic of 
HSCs is their ability to self-renew which allows the cells to persist for long durations. 
HSCs undergo asymmetric cell division, giving rise to one differentiated daughter cell 
and one quiescent stem cell. While the differentiated daughter cells lose their ability to 
self-renew, the new quiescent stem cell maintains a long-term lineage reconstitution 
potential with each division (Seita and Weissman 2010). The balance between 
differentiation and self-renewal is key in maintaining a healthy supply of blood cells. 
Aberrations in these properties can cause hematologic disorders in which patient 
exhibit a loss of HSC pool or altered differentiation potential.  
 
Early studies provided evidence that at any given time about 75% of HSCs exist in a 
quiescent state, 5% in the S/G2/M phase, and 20% in the G1 phase. More recent BrdU 
incorporation studies estimated that mouse HSCs divide approximately once in every 
57 days (Cheshier et al. 1999). More stringent studies using inducible Histone H2B-
GFP fusion protein to label cell division demonstrated that a more quiescent pool of 
HSCs divided only every 145 days (Foudi et al. 2008; Wilson et al. 2007).  
 
Prospective separation of HSCs has allowed for a better understanding of HSC 
function in normal and malignant states and have also shed light on the alterations 
within the hematopoietic system associated during the aging process.  Early studies 
investigating the frequencies of HSCs in mice showed that in the aged bone marrow, 
the number of phenotypic HSCs (lineage-cKit+sca+CD34-) is increased (Morrison et 
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al. 1996; Sudo et al. 2000). This increase in frequency is accompanied by an altered 
reconstitution potential as evident by decreased RBC and B cell output, as well as a 
myeloid bias (Chambers et al. 2007; Linton and Dorshkind 2004; Miller and Allman 
2003; Rossi et al. 2005).  
 
Aging is also associated with an increase in incidence of myeloid malignancies 
including MDS (Lichtman and Rowe 2004). Several early mutations, including 
DNMT3A, ASXL1, IDH1/2, and TET2, are found in MDS are also found in 
individuals without any overt sign of a hematologic malignancy (Busque et al. 2012; 
Jaiswal et al. 2014; Kwok et al. 2015). The presence of such mutations has been 
described as clonal hematopoiesis of indeterminate potential (CHIP). Studies of 
healthy samples from participants between the ages of 50 and 60 have shown that 95% 
of the individuals harbor mutations in DNMT3A and TET2, common preleukemic 
mutations. These mutations were found within both the myeloid and lymphoid 
compartments indicating that the mutation arose within the HSPC compartment 
(Young et al. 2016). While these mutations are correlated with an increased risk of 
hematologic malignancies, the risk is rather small, 0.5% per year overall, and despite 
the presence of clonal mutations, a majority of the people did not have hematologic 
malignancies (Jaiswal et al. 2014). Interestingly, looking at the mutational history of a 
founding clone in AML, many of the mutations were random events that occurred in 
the HSPC prior to the acquisition of the founding mutation (Welch et al. 2012). This 
suggests that accumulation of mutations in HSPCs may be a prior step in disease 
initiation.  
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Characteristics of MDS Stem Cells 
The long-term sustenance of cancer can be attributed to the cancer stem cell (CSC). In 
a study by Furth and Kahn, a single mouse leukemia cell was shown to have tumor-
initiating capacity in a recipient mouse (Furth, Kahn, and Breedis 1937). The CSC 
theory proposes that among the bulk cancer cells, a few cells act as stem cells by self-
renewing and differentiating thereby sustaining the cancer. These cells result from the 
acquisition of genetic and epigenetic mutations and are capable of propagating the 
cancer (Clevers 2011).   
 
While early studies suggested the existence of cancer stem cells (CSC) in hematologic 
malignancies, Dick and colleagues became the first to show direct evidence of the 
existence of a leukemia-initiating cell, or leukemic stem cell (LSC). In their studies, 
they showed that a subpopulation of leukemic cells expressing surface markers similar 
to normal hematopoietic stem/progenitor cells (Lineage- CD34+CD38-) were able to 
initiate leukemia in SCID mice and that this population did not consist of committed 
progenitor cells, but rather a more primitive cell population (Bhatia et al. 1997; Bonnet 
and Dick 1997; Lapidot et al. 1994; Larochelle et al. 1996). It has long been thought 
that MDS is a stem cell disease, however direct evidence was not provided until recent 
years (Pang et al. 2013; Tehranchi et al. 2010; Will et al. 2012). Early attempts to 
identify stem cell in MDS using xenograft models had been unsuccessful as the efforts 
to establish MDS in SCID mice resulted in poor grafts and did not develop signs of 
MDS (Benito et al. 2003; Grisendi et al. 2005; Kerbauy et al. 2004; Nilsson et al. 
2000; Thanopoulou et al. 2004). However, global gene expression profile studies of 
CD34+CD38-CD90+ HSCs from del5q patients demonstrated that MDS HSCs had a 
closer identity to normal HSCs than to normal progenitors suggesting that normal 
HSCs may be the origin of the disease (Nilsson et al. 2007). Additionally, 
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fluorescence in situ hybridization (FISH) studies of del5q patient HSCs and highly 
purified HSC populations from -7/7q- demonstrated that nearly all HSCs and a 
majority of the myeloid cells had the cytogenetic the defect (Nilsson et al. 2000; Will 
et al. 2012). Together, these studies provided evidence that the origin of MDS lies in 
HSCs.  
 
In addition to the cytogenetic abnormalities within MDS stem cells, quantitative 
changes have also been reported. Rigorous flow cytometry analysis of MDS patient 
samples showed phenotypic expansion of HSCs across subtypes, and an even greater 
expansion of the long-term HSCs (LT-HSCs), defined by Lin-,CD34+CD38-,CD90+ 
of high-risk cases (Pang et al. 2013; Will et al. 2012; Woll et al. 2014). High-risk 
patients were also shown to have expansion in the granulocyte-macrophage 
progenitors (GMP) (Pang et al. 2013). Across all subtypes of MDS, a decrease in 
megakaryocyte-erythroid progenitors (MEP) was observed suggesting apoptosis or a 
possible block in differentiation from common myeloid progenitors (CMP) to MEP, 
likely resulting in the anemia and thrombocytopenia observed in MDS patients (Will 
et al. 2012).  
 
MOLECULAR ABERRATIONS IN MDS 
 
Mutations Acquired in HSCs Lead to MDS  
Recent findings focusing on the molecular underpinnings in MDS stem cells revealed 
genetic and epigenetic alterations. The use of whole-genome and whole-exome 
sequencing to study limited number of cells has enabled researchers to identify many 
recurrent mutations in MDS (Bejar et al. 2011; Haferlach et al. 2014; Papaemmanuil et 
al. 2013). Mutations have been characterized in DNA methylation regulators 
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(DNMT3A, TET2, IDH1, IDH2), chromatin modification (ASXL1, EZH2), 
spliceosome machinery (SF3B1, SRSF2, U2AF1, U2AF2, ZRSR2), transcription 
factors (RUNX1, GATA2), signal transduction (NRAS, JACK2, KRAS, CBL), and 
cell cycle regulator (TP53) (Ernst et al. 2010; Gelsi-Boyer et al. 2009; Graubert et al. 
2011; Ley et al. 2010; Mardis et al. 2009; Yoshida et al. 2011). Among these 
mutations are early mutations, such as TET2, DNMT3A, ASXL1, TP53, SF3B1, and 
JAK2, which are responsible for the clonal expansion of HSCs and precede the 
development of MDS (Sperling et al. 2017).  
 
Large scale studies of MDS patients have identified more than ten genes to be 
significantly correlated with prognoses, including SF3B1, SRSF2, ASXL1, RUNX1, 
TP53, BCOR, EZH2, and U2AF1.  Additionally, the number of driver mutations at the 
time of diagnosis predicted the median leukemia free survival (Papaemmanuil et al. 
2013). Mutations in TP53, EZH2, ETV6, RUNX1, and ASXL1 were shown to be 
associated poor survival (Bejar et al. 2011) and high probability of relapse. 
Furthermore, patients with ASXL1, RUNX1, and TP53 were shown to have higher 
relapse rate and decreased overall survival after HSCT (Della Porta et al. 2016).  
 
Interestingly, early mutations associated with MDS are not exclusive to an overtly 
malignant state. Several studies have shown DNMT3A, ASXL1, SF3B1, and TET2 
mutations are present in individuals without any clinical signs of hematologic 
malignancies (Busque et al. 2012; Genovese et al. 2014; Jaiswal et al. 2014). The 
presence of such mutations is described as clonal hematopoiesis of indeterminate 
potential (CHIP). CHIP is diagnosed in patients with a somatic mutation with a mutant 
allele fraction of at least 2% and no evidence of a hematologic malignancy (Steensma 
et al. 2015).  
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Mouse Models of MDS 
Mouse models are invaluable and powerful tool in the study of cancers.  While success 
has been achieved in creating xenografts of several hematologic malignancies, MDS 
cells have proven to be challenging to establish grafts with. However, as molecular 
aberrations of MDS begins to be more understood, developing genetically engineered 
models of the disease has been made possible. In 2002, the hematopathology 
subcommittee of the Mouse Models of Human Cancers Consortium developed a set of 
guidelines describing criteria for mouse models of hematologic malignancies 
including MDS. The criteria of MDS included three points: First, the PB should have 
either neutropenia, thrombocytopenia (in the absence of leukocytosis or 
erythrocytosis), or anemia (in the absence of leukocytosis or thrombocytosis). Second, 
maturation defect in non-lymphoid cells should have dysplasia in granulocytes, 
erythrocytes, or megakaryocytes, or have at least 20% blasts in the BM. Finally, the 
disorder should not meet the criteria for another non-lymphoid leukemia(Kogan et al. 
2002).  
 
One of the more studied models of MDS is the gene fusion model, NUP98-HOXD13. 
Using a vav promoter to drive the expression in hematopoietic tissues, mice develop 
anemia and neutropenia and, in some cases, macrocytosis and thrombocytopenia. The 
BM is either normal or hypercellular and multilineage dysplasia is observed and 
eventually the mice develop AML (Choi et al. 2009). This model has been used to 
identify several secondary mutation, including, Nras and Kras, that lead to AML 
(Slape et al. 2008).  
 
An SRSF2 model was created using a hematopoietic specific Mx1-cre promotor to 
induce the Srsf2P95H mutation, found in 20-30% of MDS cases (Papaemmanuil et al. 
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2013; Yoshida et al. 2011).  SRSF2 has an RNA motif to promotes spliceosome 
assembly to allow exon inclusion. Under the Mx1-cre, hematopoietic specific 
promoter, the Srsf2P95H/+ mice developed anemia with macrocytic erythrocytes, 
leucopenia, and multilineage dysplasia in the BM (Kim et al. 2015). SRSF2 was also 
shown to be is essential for HSC survival as the mutant mice exhibited decreasing 
HSCs. The mutant form altered its RNA splicing function, affecting genes involved in 
cancer development and apoptosis, contributing to MDS development (Komeno et al. 
2015). 
 
ASXL1 mutations are reported in 15%-20% of MDS patients (Boultwood et al. 2010; 
Gelsi-Boyer et al. 2009) The conditional deletion of Asxl1 in hematopoietic cells 
develop anemia, accompanied by an increase in erythroid precursors, consistent with 
an impaired differentiation phenotype. Leukopenia was evident by reduction in B 
cells, neutrophils, and monocytes. In vitro colony cultures also demonstrated impaired 
progenitor function observed by reduction in CMP, MEP, and GMP colony output. 
HSCs also exhibited defects in self-renewal capacity upon transplantation which is not 
a characteristic of MDS stem cells. A compound Asxl1-Tet2 loss restored the self-
renewal defect induced by the Asxl1 loss, allowing the MDS stem cells to gain a 
competitive advantage (Abdel-Wahab et al. 2013).   
 
TRANSLATION 
 
Translation Levels in Hematopoietic Stem Cells  
Maintenance of tissues is largely dependent upon the function of adult stem cells 
which exhibit tight regulation of gene expression to regulate fate commitment. Among 
the regulatory processes, translational control has been shown to be important for the 
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maintenance of stem cells across different  species (Insco et al. 2013; Sampath et al. 
2008; Zhang, Qiao; Shalaby, Nevine; Buszczak 2014). Moreover, several adult stem 
cells including hematopoietic (Signer et al. 2014, 2016), neural (Llorens-Bobadilla et 
al. 2015), skeletal muscle (Zismanov et al. 2016), hair follicle (Blanco et al. 2016), 
and drosophila germline stem cells (Sanchez et al. 2016) exhibit lower protein 
translation rates than more differentiated cells.  
 
Maintenance of cellular protein, including synthesis, folding, targeting, and 
degradation, is one of the most regulated and energy consuming cellular processes 
(Buttgereit and Brandt 1995). Approximately 25-30% of the oxygen consumption 
coupled to ATP synthesis is used by protein synthesis (Brown 1997) a majority of 
which is spent on the biogenesis of components required for protein synthesis, notably 
the production, transport, and assembly of ribosomal subunits (Schmidt 1999; Strunk 
and Karbstein 2009; Warner 1999). Over the past few decades, progress in the 
structure and function of ribosomes and ribosomal proteins have provided insights into 
protein synthesis (Sonenberg and Hinnebusch 2007).  
Ribosomes are essential components of the cellular machinery catalyzing the synthesis 
of proteins. Eukaryotes have 80S ribosomes consisting of a 40S and a 60S subunit 
both of which are made up of ribosomal RNA (rRNA) and approximately 80 
ribosomal proteins. 60S, the larger subunit, is made up of approximately 50 ribosomal 
proteins (Rpl), and 3 rRNA molecules; 28S, 5.8S, and 5S. The smaller 40S subunit 
consists of about 33 ribosomal proteins (Rps) and an 18S rRNA (Strunk and Karbstein 
2009). The biogenesis and assembly of ribosomal subunits is a highly regulated 
process taking place in the nucleolus, nucleus, and the cytoplasm. rRNA (28S, 5.8S, 
5S, and 18S) are synthesized in the nucleolus and nucleolus. Ribosomal proteins are 
produced in the cytoplasm, transported to the nucleolus to assemble with rRNA 
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molecules, and then shuttled back to the cytoplasm where they mature. Protein 
translation requires the 40S and 60S ribosomal subunits, messenger RNA (mRNA), 
transfer RNA (tRNA), and initiation and elongation factors. Eukaryotic initiation 
factor (eIF) 2 recruits tRNA to the 40S subunit where the 5’ end of an mRNA is 
recruited by eIF3 and eIF4 and scanned for the start codon. Finally, the 60S subunit is 
assembled to form the final 80S complex and elongation of the amino acid chain is 
initiated (Jackson, Hellen, and Pestova 2010).   
 
Studies investigating regulation of protein synthesis in the hematopoietic system have 
shown that HSCs exhibit lower translation rates than restricted progenitors and mature 
hematopoietic cells (Signer et al. 2014, 2016). These reduced levels of translation 
were shown to be associated with the translational repressor, eukaryotic initiation 
factor 4E-binding protein 1 (4E-BP1). In a hypophosphorylated state 4E-BP1 binds to 
eIF4, preventing recruitment of the 40S subunit to mRNA (Merrick, WC; Hershey 
1996). HSCs were shown to have high levels of hypophosphorylated 4E-PB1/2 and 
4E-BP1/2 deficient mice had increased rates of translation and impaired HSC function 
showing that regulation of translation is a vital to HSC function (Signer et al. 2016).  
 
Defects in Ribosomal Proteins Lead to Impaired HSC Function 
Ribosomal proteins are integral to the protein translation machinery and HSC 
function. Rpl24, a component of the 60S subunit, deficient mice (Rpl24bst/+) exhibit 
overall decreased rates of protein synthesis. When compared to WT HSCs, HSCs from 
Rpl24 deficient mice had lower translation rates, decreased proliferation, and reduced 
reconstitution potential in transplant settings. Moreover, HSC exhaustion in Pten 
deficient mice, caused by increase translation rates, was rescued in the Rpl24bst/+ 
background (Signer et al. 2014). In another study, deletion of notchless (Nle), essential 
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for 60S subunit maturation, results in the entry of quiescent HSCs into cell cycle and 
ultimately leads to their exhaustion. Interestingly, no increase in cell death pathways 
were observed leading to the possibility that the defects in ribosome biogenesis may 
lead to premature differentiation of HSCs (Le Bouteiller et al. 2013), an mechanism 
that has been demonstrated in HSCs and several other stem cells as a response to stress 
(Inomata et al. 2009; Li, Mangmang, Yunlong He, Wendy Dubois, Xiaolin Wu, 
Jianxin Shi 2013; Wang et al. 2012). Additionally, Runx1 deficient HSCs having 
impaired ribosome biogenesis have been shown to have decreased rates of apoptosis 
under homeostasis and genotoxic stress conditions (Cai et al. 2011, 2015). Together 
these studies demonstrate the delicate balance of protein synthesis required for proper 
HSC function.  
 
Ribosomal Defects in Hematologic Malignancies 
Defects in ribosomal biogenesis have long been implicated in congenital BM failure 
syndromes including diamond-blackfan anemia (DBF),  Shwachman-Diamond 
syndrome (SDS), and x-linked dyskeratosis congenital (DKC) (Boocock et al. 2003; 
Draptchinskaia et al. 1999; Heiss et al. 1998). DBA, clinically characterized by 
anemia, macrocytosis, reticulocytopenia, and a block in erythropoiesis, is associated 
with mutations in several ribosomal proteins, including RPS19 and RPS24 which led 
to decrease 40S subunits (Choesmel V, Bacqueville D, Rouquette J, Noaillac-Depeyre 
J and Cretien A, Leblanc T, Tchernia G, Da Costa L 2007; Choesmel V, Fribourg S, 
Aguissa-Toure AH, Pinaud N, Legrand P and Gleizes PE 2008; Draptchinskaia et al. 
1999). DBA was the first disease to be linked with defects in ribosomal proteins and 
became the first of a group of disorders to be categorized as ribosomopathies. A 
common feature of many of these syndromes is the increased risk of developing 
cancers including MDS (Blanche P. Alter, Neelam Giri 2009; Donadieu et al. 2005).  
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Del5q syndrome is the most common chromosomal abnormality in MDS patients and 
is classified as having low risk of transformation to AML and long survival (Van Den 
Berghe et al. 1974; Jacqueline Boultwood, Sian Lewis 1994). Ribosome biogenesis 
defected in MDS were first shown in studies of del5q patients showing haplo-
insufficiency of two important ribosomal genes, RBM22 and RPS14 (Boultwood et al. 
2007).  RPS14 deficiency, causes defects in 18S RNA processing and lead to reduced 
levels of the 40 S subunit.  Using RNAi to deplete RPS14, it was shown that haplo-
insufficiency of RPS14 was played a causative role in development of the disease 
(Ebert et al. 2013).  
 
Evidence of defects in ribosomal proteins in non-del(51) MDS patients suggested that 
ribosome biogenesis defects may not be limited to del5q (Czibere et al. 2009; 
Davendra P. Sohal, Andrea Pellagati, Li Zhou, Yongkai Mo, Joanna B. Opalinska, 
Christina Alencar, Christoph Heuck, Amittha Wickrema, Ellen Friedman, John 
Greally, Benjamin L. Ebert, Jonathan Warner 2008; McGowan et al. 2011). In a large 
scale study, CD34+ cells from 72 non-del5q MDS patients and 11 del5q MDS patients 
were screened and it was found that 72% of the non-del5q patients had decrease in 
RPS14 expression (Czibere et al. 2009). In another study, 97 MDS patients, 54 low-
risk and 43 high-risk, RPL23, inhibitor of apoptosis, was overexpressed in high-risk 
patients and possibly caused disease progression (Qi et al. 2017).  
 
Therapeutic Strategies 
The dysregulation of protein synthesis implicated in many other cancers has provided 
a window for therapeutic intervention. Inhibiting ribosome biogenesis and translation 
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initiation by targeting RNA Pol I, EIF4A, EIF4e, EIF2S1, mTOR, and dual PI3K-
mTOR have been explored.  
 
Aberrant regulation of the mTOR pathway has been implicated in several hematologic 
malignancies including AML, T-cell acute lymphoblastic leukemia (T-ALL, chronic 
myelogenous leukemia (CML), and high-risk MDS (Altman and Platanias 2008; 
Teachey, Grupp, and Brown 2010). mTOR, hyperactive in many cancers, forms two 
complexes, mTORC1 and mTORC2 and drives anabolic pathways, including protein 
synthesis and ribosome production.  Rapamycin, an mTORC1 inhibitor, has been 
proposed as a therapy for cancer. Rapamycin, which specifically targets mTORC1, has 
been clinically used since 2000 to prevent organ transplant rejection because of its 
immunosuppressant functions (MacDonald 2001).  
 
Cycloheximide (CHX) has been shown to block the elongation phase of eukaryotic 
translation. It binds the ribosome and inhibits eEF2-mediated translocation (Hardesty 
1971). CHX allows one complete translocation cycle to proceed before halting any 
further elongation (Pestova and Hellen 2003). CHX has been shown to have 
antiproliferative effects in leukemia cell lines (Myasnikov et al. 2016), however, since 
CHX has teratogenesis and reproductive side-effects it is not recommended to be used 
in vivo.  
 
Homoharringtonine is a translation elongation inhibitor and acts by binding to the 80S 
ribosome and inhibits protein synthesis. Hamoharringtonine has been approved by the 
FDA as a therapy for CML (Alvandi et al. 2014) and is in trials for AML (Alvandi et 
al. 2014).  
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Several inhibitors of translation have been implicated in treating hematologic disease, 
however they have not shown to have specific effects on CSCs. As ribosomal defects 
are pronounced in MDS and other bone marrow failure diseases, targeting ribosomes 
further may serve as a powerful therapy for depleting MDS stem cells. In this 
manuscript, we describe using the Vav-cre-Asxl1fl/fl-Tet2 fl/fl and Mx-cre- Asxl1fl/fl-
Tet2 fl/fl to assess the role for the aging stem cell in MDS pathogenesis and the 
targeting of the 60S ribosomal subunit in the Vav-cre-Asxl1fl/fl-Tet2 fl/fl mouse model 
of MDS stem cells using an immunotoxin, saporin.  
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CHAPTER TWO 
THE ROLE OF AGING STEM CELLS IN MDS PATHOGENESIS 
 
INTRODUCTION 
 
Aging is associated with changes in the hematopoietic system due to alterations in HSCs 
including increased HSC frequency, reduced red blood cells and lymphocytes, an 
increase in myeloid cells (Chambers et al. 2007; Jaiswal et al. 2014; Linton and 
Dorshkind 2004; Miller and Allman 2003; Morrison et al. 1996; Pang et al. 2011; Rossi 
et al. 2005; Sudo et al. 2000), and clonal hematopoiesis (Jaiswal et al. 2014; Steensma 
et al. 2015).  In addition to these changes, aging is also associated with an increased risk 
of developing malignancies originating from HSCs including MDS (Busque et al. 2012; 
Genovese et al. 2014; Jaiswal et al. 2014; Jan et al. 2012; Kwok et al. 2015).  
Hematologic changes observed in MDS, including anemia, decreased lymphoid output, 
myeloid bias, increased HSC frequency, and clonal expansion are similar to those 
observed in the normal elderly population (Table 2.1). We hypothesized that in addition 
to the somatic mutations and karyotypic alterations, MDS pathogenesis is also 
dependent upon factors present in normal aging background.   
 
Table 2.1: Hematopoietic Features in Aging and MDS  
 
 
Age MDS 
Increased HSC number ✔ ✔ 
Decreased HSC long-term reconstitution potential ✔ ✔ 
Myeloid Differentiation Bias ✔ ✔✔✔ 
Decreased lymphoid production ✔ ✔✔✔ 
Decreased red cell production ✔ ✔✔✔ 
Clonal Expansion ✔ ✔✔✔ 
Risk of MDS/AML ✔ ✔✔✔ 
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Given that MDS arises from HSCs and the elimination of MDS HSCs is required for a 
cure, it is important to identify all the factors that regulate MDS HSC function. In this 
study we investigated the contribution of aging in the development and severity of 
MDS phenotypes. We used the Vav-cre-Asxl1fl/fl-Tet2 fl/fl and Mx-cre- Asxl1fl/fl-Tet2 
fl/fl mouse models of MDS to address two questions: 1) Does the age of the cell-of-
origin impact MDS pathogenesis and 2) Does disease chronicity impact MDS stem 
cell phenotype.  
 
RESULTS 
 
The Cell-of-Origin Impacts MDS Pathogenesis 
We proposed to use Mx-cre- Asxl1fl/fl-Tet2 fl/fl conditional null mice to study the effect 
of varying the age when MDS initiating genetic deletions are induced on MDS disease 
phenotype and HSC function, predicting that older mice induced to develop MDS would 
manifest disease with faster kinetics and a more pronounced phenotype. 
 
Initial transplants were set up using 2X106 mononuclear cells (MNC) from Mx-cre- 
Asxl1fl/fl-Tet2 fl/fl (CD45.2) mice of varied ages (5, 12, and 22 months) into lethally 
irradiated CD45.1 recipients. At 16 weeks following stable engraftment, Asxl1 and 
Tet2 deletions were induced using polyI:polyC (Figure 2.1a). Following 
establishment of nearly 100% chimeras (Figure 2.2b), mice were tracked long-term 
for development of disease based on peripheral blood and bone marrow analysis.  
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FIGURE 2.1. Generation of Stably Engrafted Recipients 
a.  Experimental Setup. 2x106 MNC from Mx-cre- Asxl1fl/fl-Tet2 fl/fl or C57BL6 WT 
mice were transplanted into lethally irradiated mice. 16 weeks after transplant, deletion 
of Asxl1 and Tet2 was induced by 5 intraperitoneal injections of polyI:polyC every 
other day at a dose of 20mg/kg of body weight.  
b. 16-week Total Peripheral Blood Donor Chimerism. Donor chimerism represented by 
frequency of donor cells of total CD45+ cell population. 
 
 
6 months after the induced deletion of Asxl1 and Tet2 genes, peripheral blood counts 
show groups receiving old MDS cells exhibit lower white blood cell, specifically in 
the neutrophil compartment, when compared to groups receiving old WT cells (Figure 
2.2a). The neutropenia was confirmed with the reduction of Gr1-+Mac-1+ 
granulocytes in the peripheral blood by flow cytometry analysis (Figure 2.2b). 
Lineage analysis in the peripheral blood showed no difference in monocyte, B cell, 
and T cells at this time point. (data not shown).  
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FIGURE 2.2. Recipients of Old Donor HSCs Exhibit Leukopenia 
a. White Blood Cell and Neutrophil Counts. Complete blood counts measured using 
HemaVet 950.   
b. Peripheral Blood Flow Cytometry Analysis of Granulocytes. Granulocyte frequency 
as measured by Gr-1+Mac-1+ of total Ter119- cells. All data represent mean±s.d. *, 
p<0.05; **, p<0.01; ***, p<0.001.  
 
 
As expected, groups receiving young MDS cells had lower hematocrit percentage 
when compared to groups receiving young WT cells, however, this reduction did not 
become evident until 12-months post-deletion (Figure 2.3b). At the 6-month time 
point, hematocrit percentage were elevated in recipients of old MDS cells indicating a 
possible compensatory mechanism to produce excess RBC in response to an initial 
decrease in output (Figure 2.3a and 2.3b). Alterations in platelet counts are observed 
in normal aging and in this transplant, old WT donors exhibited reduced platelet 
output persistent from 6-months onward (Figure 2.3a and 2.3b). This reduced platelet 
phenotype was not observed in recipients of old MDS donor cells possibly indicating 
an intrinsic advantage of MDS cells or the result of an advantage due to a young 
microenvironment. These findings are consistent with the known myeloid dysplasia 
and leukopenia in MDS patients and mice.  
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FIGURE 2.3. Recipients of Old Donor HSCs Decrease in RBC Output  
a. Hematocrit % and Plate Count at Six-Months Post-Deletion.  
b. Hematocrit % and Plate Count at Twelve-Months Post-Deletion. Complete blood 
counts measured using HemaVet 950.  All data represent mean±s.d. *, p<0.05; **, 
p<0.01; ***, p<0.001.  
 
As expected, recipients of old MDS cells also exhibited an expansion of the LSK and 
CMP populations in the bone marrow (Figure 2.4a). This expansion is consistent with 
the previously described MDS phenotype in humans and mice. Kaplan-Meier survival 
curves of groups transplanted with young, intermediate, and old WT and mutant cells 
exhibited reduction in survival among recipients of old donor cells (Figure 2.4b). 
Together, these data suggest that the age of a stem cell at the time of deletion plays a 
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role in disease phenotype including neutropenia, defects in red cell compartment, 
expansion of HSCs, as well as overall survival.  
 
 
FIGURE 2.4. Deletion of Asxl1-Tet2 Results in the Expansion of HSPCs and Reduced 
Survival of Recipients of Old Stem Cells 
a. Bone Marrow HSPC Flow Cytometry Analysis Twelve-Months Post-Deletion. 
Bone marrow aspirates were performed and HSPC compartments were analyzed by 
flow cytometry.  
b. Kaplan-Meier Survival Curves. All data represent mean±s.d. *, p<0.05; **, p<0.01; 
***, p<0.001.  
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Impact of Disease Chronicity on MDS Stem Cell Phenotype 
To assess the impact of disease chronicity on MDS pathogenesis, transplants were set 
up using mononuclear cells from Vav-creTet2fl/flAsxl1fl/fl (CD45.2) constitutive double 
knock out mice of varied ages (5, 14, and 23 months) into lethally irradiated CD45.1 
recipients. Following establishment of nearly 100% chimeras, mice were tracked long-
term for development of disease based on peripheral blood and bone marrow analysis.  
Long-term cell counts showed no significant differences between the various groups 
(Figure 2.5). As MDS is characterized by an increase in severity of anemia with 
disease progression, this similarity in RBC between the young and old mutant 
recipients was unexpected.  
 
FIGURE 2.5. No Significant Differences in Long-Term Peripheral Blood Counts of 
Young and Old Mutant Recipients. Complete blood counts measured using HemaVet 950.  
All data represent mean±s.d. *, p<0.05; **, p<0.01; ***, p<0.001.  
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Examination of the bone marrow at the 34 and 60-week time point showed 
maintenance of high over all donor chimerism as well as chimerism within 
hematopoietic stem & progenitors (data not shown). Further examination showed 
groups receiving intermediate or old MDS cells exhibit lower GMP frequencies when 
comparted to groups receiving WT cells (Figure 2.6). This is consistent with the 
previously known findings that the Vav-creTet2fl/flAsxl1fl/fl mice exhibit age-
dependent myeloid dysplasia. Surprisingly, we also observed that mice receiving MDS 
cells exhibited lower LSK frequencies (Figure 2.6). Vav-creTet2fl/flAsxl1fl/fl mice 
have been shown to have rescue the impaired self-renewal seen in the single Asxl1-
deficient mice. These findings suggest a non-cell intrinsic mechanism leading to the 
lower LSK frequencies. Furthermore, when comparing young, intermediate, and old 
MDS cell recipients, no significant differences in HSCS frequencies was observed  
 
As expected, groups receiving young WT cells showed increased survival when 
compared to those receiving old WT cells. Interestingly, this difference was not 
observed when comparing groups receiving young, intermediate, and old MDS cells. 
Additionally, groups receiving old MDS cells had a significant increase in survival 
when compared to groups receiving old WT cells (Figure 2.7). As donor chimerism 
was maintained at equally high levels in these two groups (Data not shown), we have 
ruled out that this is due to inability of MDS cells to engraft. Together, these data 
demonstrate that constitute deletion of Asxl1 and Tet2 did not alter disease 
progression with varying the age of the stem cell. This was evident by similar 
peripheral blood counts, LSK frequencies, as survival of recipients of mutant cells.  
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FIGURE 2.6. Bone Marrow HSPC Frequencies. Bone marrow aspirates were performed 
on recipient mice at 34 and 60-weeks post-transplant. LSK, CMP, GMP, and MEP 
frequencies were determined by flow cytometry analysis.   
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FIGURE 2.7. Kaplan-Meier Survival Curve All data represent mean±s.d. *, p<0.05; **, 
p<0.01; ***, p<0.001.  
 
 
DISCUSSION 
 
In this study, we examined the effects of aging stem cells on MDS pathogenesis. 
Using a genetically accurate model of MDS, we show that hematopoietic specific 
deletion of Asxl1 and Tet2 in older cells manifests disease with faster kinetics as 
evident by decreased disease latency, greater disease severity, and decreased survival. 
Additionally, constitutive deletion of Asxl1 and Tet2 in young, intermediate, and old 
stem cells resulted in manifestation of disease at a similar rate and recipient mice 
exhibited no differences in overall survival. While age of the cell of origin impacts 
disease pathogenesis, disease chronicity itself does not impact MDS phenotype. Cell 
extrinsic factors may play a role in full manifestation of MDS.  
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CHAPTER THREE 
TRANSLATION IN MDS AND THE DEPLETION OF HSCS WITH 
CD117-SAPORIN IMMUNOTOXIN 
 
INTRODUCTION 
 
Defects in ribosomal proteins have been reported across different subtypes of MDS 
(Alkhatabi et al. 2016; Boultwood et al. 2007; Cai et al. 2015; Czibere et al. 2009; 
Davendra P. Sohal, Andrea Pellagati, Li Zhou, Yongkai Mo, Joanna B. Opalinska, 
Christina Alencar, Christoph Heuck, Amittha Wickrema, Ellen Friedman, John 
Greally, Benjamin L. Ebert, Jonathan Warner 2008; Lansdorp et al. 1990; McGowan 
et al. 2011). As these defects are pronounced in MDS stem cells they may be 
functioning on limited resources, making the more vulnerable targets of ribosome 
inhibitors.   
 
Ribosome-inactivating proteins (RIPs) are toxins which specifically and irreversibly 
inhibit protein synthesis by cleaving a specific adenine residue (A4324) on the 28S 
ribosomal subunit. Hundreds of RIPs have been isolated from plants and bacteria and 
have been shown to have a range of toxicity and are classified as type I or type II. 
Type I RIPs are single A-chain proteins with N-glycosidase enzymatic activity while 
type II RIPS have two polypeptide chains (A and B chain). The A-chain has enzymatic 
function and the B-chain is a lectin-like peptide with an affinity for galactose allowing 
translocation through the plasma membrane making type II RIPS more toxic (Schrot, 
Weng, and Melzig 2015; Stirpe 2004). In 1891, ricin and abrin became the first RIPs 
to be identified by Paul Ehrlich who identified the proteins and raised antibodies 
against them (Olsnes 2004). Several decades later the enzymatic activity was 
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described and ricin and related proteins were characterized as proteins that inhibit 
translation by damaging ribosomes, or ribosome-inactivating proteins (Olsens and Pihl 
1972).  
 
Saporin, isolated from Saponaria officinalis L (soapwort), is a type I RIP with nine 
forms. Saporin-6 is the most abundant form and conserves the RNA N-glycosidase 
activity specific to A4324 of the 28S ribosomal subunit. While Saporin-6 lacks the B-
chain, some groups have reported internalization of saporin by endocytosis in some 
cell types (Bagga, Seth, and Batra 2003; Cavallaro et al. 2018). Once internalized, 
saporin permanently inactivates the 28S subunit, blocking the binding of EF-1 and the 
formation of EF-2. This prevents the translocation of tRNA from the A site to the P 
site of the ribosomal complex ultimately leading to cell death (Endo and Tsurugi 
1988).  
 
Saporin molecules have been conjugated to antibodies of cell surface markers to 
generate immunotoxins against several cancer types, including hematologic 
malignancies (Polito et al. 2013). The first clinical trial used CD30-Saporin conjugates 
to treat refractory Hodgkin lymphoma patients. While the therapeutic effect was 
limited to a few months, the immunotoxin was successful in reducing the tumor mass 
by up to 60% (Falini et al. 1992).  
 
In a recent study, saporin conjugated to a CD45.2 internalizing antibody was used to 
deplete the BM of C57BL/6 wild-type mice allowing for nearly 100% engraftment of 
donor cells. Despite CD45.2 being expressed on most hematopoietic cells in the BM, 
CD45-Saporin conditioning had minimal effects on most of the mature BM cells 
avoiding toxicity generally caused by irradiation conditioning.  This study 
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demonstrated a novel method of conditioning patients for HSCT (Palchaudhuri R et al 
2016).  
 
Here we aim to test whether saporin treatment can deplete MDS stem cells with 
minimal effects on the rest of the BM architecture. As standard conditioning regimen 
for HSCT for MDS patients can be too aggressive, affecting cells beyond the target, a 
more targeted and less aggressive regimen can serve as a replacement, making it 
possible for older patients with comorbidities to be eligible for HSCT. Additionally, as 
MDS HSCs have been shown to have global reductions in translation levels when 
compared to normal counterparts, they may have been more susceptible to further 
inhibition of translation.  
 
 
RESULTS 
 
Normal Human and MDS Patient HSCs exhibit decreased translation rates 
We first sought to quantify the rate of translation in human HSCs by using an op-puro 
incorporation assay. While one of the most well-established methods of measuring 
global changes in protein synthesis is dependent upon the incorporation of 
radiolabeled amino acids, such as 35S methionine and 35S cystine, in newly synthesized 
polypeptides, we needed a flow cytometry-based assay to measure protein synthesis of 
HSCs within a bulk population. A more recent assay using P-propargyl-puromycin 
(OP-Puro) has been developed to detect protein synthesis by fluorescence and for cells 
in vitro and in vivo. OP-Puro, an alkyne puromycin analog, when taken up by cells 
during active protein synthesis forms covalent polypeptide-OP-Puro conjugates and 
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nascent polypeptides can be quantified using fluorescence-based techniques (Liu et al. 
2012).  
 
Umbilical cord blood is a rich source for human HSCs and progenitors. Assessing 
protein translation in CD34 enriched cord blood cells, we found that when compared 
to total CD45+ cells, progenitors (CD45+CD34+CD38+) and more strikingly, HSCs 
(CD45+CD34+CD38) exhibit lower op-puro incorporation (Figure 3.1a). We further 
assessed op-puro incorporation in cells from two normal human bone marrow samples 
and observed more than a 50% reduction in translation within the progenitors and 
HSC compartment when compared to total CD45+ cells (Figure 3.1b). These results 
demonstrate that human HSC and progenitors from both cord blood and BM, exhibit 
reduced translation rates.  
 
We next sought to assess translation in stem cells from MDS patient BM samples. We 
obtained a BM aspirate sample from a patient with refractory anemia with excess 
blasts (RAEB-1), 6%.  Patients with RAEB-1 have multiple cytopenias and have 
between 5-9% blasts in the BM. Similar to the observations in normal BM HSCS, op-
puro incorporation in HSPCs was less than half of the levels as total CD45+ cells 
(Figure 3.2a).  
 
To further validate the reduced translation in MDS HSCs, we compared monosomes 
and polysomes from a healthy patient and an MDS patient with RUNX1 and EZH2 
mutations. First using CHX to freeze translating ribosomes with mRNA transcripts on 
FACS sorted CD34 cells, cell lysates were added to sucrose gradients followed by 
centrifugation and fractionation. Early fractions representing monosomes had higher 
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FIGURE 3.1. Cord Blood and BM HSCs Exhibit Reduced Translation 
Total fraction represents CD45+ cells. Progenitors cells are phenotypically characterized as 
CD45+ CD38+ CD34+ fractions and HSCs are characterized by CD45+ CD38- CD34+. 
Representative histograms show OP-puro MFI comparing progenitor and HSC populations.  
a. OP-Puro MFI in Cord Blood. Representative gating strategy, OP-Puro MIF 
histogram, and bar graphs. 300,000 CD34 enriched cord blood cells. N=3. All data 
represent mean±s.d. *, p<0.05; **, p<0.01; ***, p<0.001.  
b. OP-Puro MFI from Two Normal BM Patient Samples. Representative gating 
strategy, OP-Puro MIF histogram, and bar graphs. 300,000 CD34 enriched bone 
marrow cells.  
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FIGURE 3.2. MDS HSCs Exhibit Reduced Translation 
a. OP-Puro Incorporation in an MDS Patient BM Samples Total fraction 
represents CD45+ cells. Progenitors cells are phenotypically characterized as 
CD45+ CD38+ CD34+ fractions and HSCs are characterized by CD45+ CD38- 
CD34+. Representative histograms and bar graph show OP-puro MFI comparing 
total CD45+, progenitor, and HSC populations.  
b. Monosomes and Polysomes of Healthy and MDS patient BM sample. CD34+ 
cells from healthy and MDS patient samples were treated with 10mg/ml of CHX 
followed by centrifugation and fractionation. Ribosomal RNA content is plotted 
against each fraction.  
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 ribosomal RNA (rRNA) content in CD34+ MDS cells when compared to the healthy 
control indicating more free ribosomes. Late fractions, representing the polysomes, 
showed lower rRNA content in CD34+ MDS cells when compared to the healthy 
control indicating fewer ribosomes bound to mRNA transcripts (Figure 3.2b). These 
two MDS patient samples both showed reduced translation in HSPCs however, 
analysis of larger sample number across different MDS subtypes will be necessary to 
validate these findings.  
 
Mouse Models of MDS Exhibit Reduced Translation 
We next wanted to test the efficacy of saporin in depleting MDS stem cells. To 
investigate this, we first established whether HSCs from mouse models of MDS also 
exhibit decreased translation. We began with an SRSF2 mouse model which carries a 
mutation, found in 20-30% of MDS patients (Papaemmanuil et al. 2013; Yoshida et al. 
2011), altering its splicing function. cKit enriched cells from an SRSF2 mutant and an 
SRSF2 wild-type were run through a sucrose gradient rRNA content across ten 
fractions was measured. cKit enriched cells from the mutant mouse had higher rRNA 
content within the monosome fractions and lower rRNA content within the polysome 
fractions when compared to wild-type cells indicating reduced translation in the 
mutant cells (Figure 3.3a).  
 
Additionally, we measured translation in the Vav-cre-Asxl1fl/fl-Tet2 fl/fl mouse model. 
Wild-type and mutant cKit enriched cells were assessed for op-puro incorporation. 
Wild-type HSCs (Lineage- Sca-1+ cKit+) trended toward having lower translation 
than progenitors and mutant HSCs were shown to have significantly lower translation 
than mutant progenitors. Moreover, when compared to wild-type HSCs, mutant HSCs 
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had reduced translation (Figure 3.3b). Taken together, the SRSF2 and Asxl1-Tet2 
models of MDS both exhibit reduced translation in HSCs.  
 
In Vivo Saporin Treatment Depletes HSCs  
To mimic a human MDS patient BM, wild-type mononuclear cells from UBC-GFP 
mice and mutant cells from Vav-cre-Asxl1fl/fl-Tet2 fl/fl mice were transplanted at a 1:1 
ratio into lethally irradiated recipients. 12-weeks post-transplant, mutant and GFP 
donor cells were stably engrafted at nearly the initial transplanted ratio (Figure 3.4a).  
Monocytes and B cells chimerism levels were equally between donor mutant and 
donor GFP cells and T cells were mostly derived from mutant cells. Granulocytes 
were mostly derived from wild-type donor cells instead of mutant donor cells evidence 
of the neutropenia exhibited by Vav-cre-Asxl1fl/fl-Tet2 fl/fl mice (Figure 3.4b).  
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FIGURE 3.3. HSCs in Mouse Models of MDS Have Reduced Translation 
a. Monosome and Polysomes of CKit Enriched BM cells of SRSF2 WT and SRSF2 
Mutant. cKit enriched cells were treated with 10mg/ml of CHX followed by 
centrifugation and fractionation. Ribosomal RNA content is plotted against each 
fraction. 
b. OP-Puro Incorporation in Asxl1-Tet2 Mutants. Progenitors cells are phenotypically 
characterized as Lineage- Sca-1- cKit+ fractions and HSCs are characterized by 
Lineage- Sca-1+ cKit+ Representative bar graph shows OP-puro MFI comparing in 
progenitor, and HSC populations from mutant and WT mice.   
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FIGURE 3.4. Generation of WT UBC-GFP and Asxl1-Tet2 Chimeric BM  
a. Generation of Vav-cre-Asxl1fl/fl-Tet2 fl/fl /UBS-GFP Mice. 10x106 MNC from 
Vav-cre-Asxl1fl/fl-Tet2 fl/fl (CD45.2) and 10x106 MNC from UBC-GFP (CD45.2) 
were transplanted via retro orbital injection into lethally irradiated pepboy 
(CD45.1) recipients.  
b. Sixteen-week Total Peripheral Blood and Lineage Chimerism. *, p<0.05; **, 
p<0.01; ***, p<0.001 
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Following stable engraftment, mice were treated with a biotinylated CD45.2 antibody, 
CD117, or IgG, conjugated to saporin-streptavidin. The CD45.2-Saporin immunotoxin 
has been shown to deplete HSPCs specifically from C57BL/6 BM (Palchaudhuri R et 
al 2016). As CD117 is expressed on mainly immature populations in the BM, we also 
tested the efficacy of HSC depletion when combined with saporin.  BM aspirates were 
sampled immediate before the immunotoxin treatment and 8 days post-treatment. As 
previously described, 8 days was sufficient time to observe depletion of HSCs from 
mouse BM (Palchaudhuri R et al 2016). A reduction in total LSK and LSK CD150+ 
cells was observed with both CD117-Saporin and CD45-Saporin treatment (Figure 
3.5a). Change in chimerism levels of each cell type within the LSK and progenitor 
compartments was also measured. Post-treatment, recipient (CD45.1) LSK and 
progenitor chimerism mostly increased, likely a result of the decreasing contributions 
from t wild-type GFP and mutant cells. Contributions of GFP and mutant cells within 
the LSK and progenitor compartment trended towards a decrease upon CD117-saporin 
and CD45-saporin treatment (Figure 3.5b) indicating that a single dose of the 
immunotoxin can deplete HSPCs in vivo.  
 
Treatment with Saporin Allows Engraftment of Donor Cells  
Myeloablative conditioning regimen for a HSCT aims to clear the BM of dysplastic 
cells and is followed by the infusion of healthy stem cells. Engraftment of healthy 
stem cells indicate sufficient depletion of resident HSCs has opened niche spaces for 
donor cells. To test whether saporin treatment can serve as a conditioning regimen for 
HSCT for MDS patients, we treated GFP and mutant chimeric mice with CD117- 
saporin and CD45-saporin, and followed up with a transplant of F1 donor cells 8 days 
 
 
 43 
 
 
FIGURE 3.5. In Vivo Depletion of WT UBC-GFP and Asxl1-Tet2 HSCs Generation of 
Vav-cre-Asxl1fl/fl-Tet2 fl/fl /UBS-GFP Mice. 
a. Eight-Day Post-Treatment Frequencies. LSK and LSK CD150+ frequencies within 
total CD45 cells in IgG, CD117, and CD45.2 treated groups. 12ug of CD117-saporin 
and 24ug of CD45-saporin were administered retro-orbitally.  
b. Change in LSK and Progenitor Chimerism. Pre and post IgG, CD117, and CD45.2 
treatment. Each dot represents a single mouse and colors are coordinated to represent 
the same mouse pre and post-treatment.   
 
 
later (Figure 3.6a).  Following the transplant, peripheral blood analysis showed that 
CD117 and CD45 – saporin treated groups had approximately 60-70% engraftment of 
F1 cells 12 weeks after the transplant (Figure 3.6b).  
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FIGURE 3.6. Treatment with Saporin Allows Engraftment of F1 Donor Cells  
a. Eight-Days after IgG, CD117, and CD45– Saporin Treatment. Chimeric mice 
were transplanted with 20x106 WBM cells F1 donor cells.  
b. Twelve-Week F1 chimerism levels.  *, p<0.05; **, p<0.01; ***, p<0.001 
 
 
To assess whether engraftment of F1 cells was the result of depletion of more wilt-
type GFP cells or mutant cells, we measured changes in GFP and mutant chimerism 
levels after saporin treatment. Comparing chimerism levels, we observed that both 
GFP and mutant cells were depleted and mutant cells, despite having lower rates of 
translation, likely were not more susceptible to saporin treatment (Figure 3.7a).  
Looking within granulocytes, monocytes, b cells, and t cells, chimerism levels of GFP 
and mutant cells across all lineages were both reduced (Figure 3.7b). These data 
demonstrate that while saporin did not preferentially deplete MDS stem cells, it 
allowed for sufficient depletion of all HSCs to allow for donor cell engraftment.  
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FIGURE 3.7. GFP and Mutant Peripheral Blood Chimerism Decrease After Saporin 
Treatment  
a. Change in Total GFP and Mutant Chimerism Twelve Weeks After Saporin 
Treatment.  
Change in Lineage Chimerism of GFP and Mutant Cells Twelve Weeks After Saporin 
Treatment. *, p<0.05; **, p<0.01; ***, p<0.001 
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DISCUSSION 
 
We have shown using op-puro incorporation and a sucrose gradient assay that in both 
mouse models of MDS and in human cord blood and BM samples, normal and MDS 
HSCs exhibit reductions in global translation when compared to bulk and progenitor 
populations. Reduced translation in HSPCs of the two MDS patient samples evaluated 
here represent only a small subset of MDS patients. Additional samples will be 
required to validate the findings and to correlate the reduction in translation to known 
defects in ribosome biogenesis.  
 
Using mononuclear cells from the genetically accurate Vav-cre-Asxl1fl/fl-Tet2 fl/fl MDS 
model and wild-type UBC-GFP mice we generated chimeric BM representing the 
normal and dysplastic cells present in MDS patient BM prior to disease progression. 
We transplanted equal number of cells from GFP and mutant mice and observed that 
engraftment efficiency of both cells was equal and total chimerism levels remained 
equal long-term. These mice were treated with the immunotoxin and evidence of GFP 
and mutant HSPC depletion was observed from BM aspirates 8 days after treatment.   
 
Subsequent donor cell transplant lead to high engraftment indicating elimination of 
resident HSPCs opened niche space for donor cells. We also observed that the IgG 
treated groups also exhibited increase F1 engraftment and reduced chimerism levels 
specifically within the GFP compartment. While the internalization of IgG by some 
BM cells explains the depletion, the reasons for the specificity of GFP cell depletion is 
not clear. 
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We had observed that HSCs from mutant mice have lower translation when compared 
to wild-type, and hypothesized that perhaps the reduced translation would make them 
more susceptible to an immunotoxin that targets the translation machinery. However, 
we did not see a selective depletion of mutant HSCs. Nonetheless, sufficient depletion 
of mutant HSCs allowed engraftment of donor cells making the treatment a potential 
non-genotoxic conditioning regimen for transplants.  
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CHAPTER FOUR 
EXPLORING THE MECHANISM OF SAPORIN-INDUCED CELL 
DEPLETION  
 
INTRODUCTION 
 
While our data shows depletion of wild-type and MDS HSCs in vivo, an 
understanding of how saporin causes the depletion needs to be determined.  
In early studies, evidence of saporin cytotoxicity has mostly been obtained by 
determining inhibition of protein synthesis or determining cell viability of treated cells 
compared to controls (Bolognesi et al. 2005; Polito et al. 2009; Tazzari et al. 1999, 
2018).  In an early study, saporin conjugated to anti-CD2 mAb showed inhibition of 
proliferation and an inhibition of protein synthesis measured by 3H-leucine 
incorporation by the SKW-3 T-ALL cell line after 48 hours of incubation with the 
immunotoxin (Tazzari et al. 2018).   
 
We sought to determine whether the immunotoxins CD117-saporin and CD45-saporin 
also inhibited translation of HSPCs in wild-type and mutant Vav-cre-Asxl1fl/fl-Tet2 fl/fl. 
We also assessed protein translation rates in cord blood units to determine whether 
human HSPCs respond to the immunotoxins by the same mechanism. We evaluated 
protein synthesis by the op-puro incorporation assay and also assessed cell viability as 
well as functional effects of the immunotoxin treatment.  
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RESULTS 
 
We began the study by using the multipotent mouse erythroid myeloid lymphoid 
(EML) cell line to evaluate in vitro effects of the immunotoxins. We verified that 
EML cells express CD117 receptor and contained both Sca-1+ LSK and Sca-1- 
progenitor cell populations. Dose titration curve of the CD117-saporin treatment was 
generated based on cell viability after 72 hours of culture (Figure 4.1a). Using 10nM 
of both CD117 and saporin, we demonstrated that within 24 hours, saporin molecules 
were robustly internalized with CD117-saporin treatment. No shift was observed in 
the saporin only group indicating that only when conjugated with the internalizing 
antibody can saporin be transported into the cell (Figure 4.1b). To assess whether 
apoptosis was induced at this time point we did an annexin V and 7AAD stain and it 
revealed little to no increase in apoptotic cell frequencies (Figure 4.1c). We followed 
up with a cell cycle stain to determine whether any shifts in cell cycle status occurs 
with the immunotoxin and observed a decrease in S phase accompanied by an increase 
in G1 phase indicating a possible G1 arrest (Figure 4.1c). These data demonstrate that 
at the 24-hour time point CD117-saporin is efficiently internalized and while no 
induction of apoptosis occurs, cells may enter into a G1 arrest. As EML cells treated 
with CD117-saporin showed greater changes at 72 hours, apoptosis and cell cycle 
changes need to me measured at timepoints beyond 24 hours.  
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FIGURE 4.1. In Vitro Effects of Saporin on EML Cells  
a. EML Cell Flow Cytometry and Dose Titration.  
b. Internalization of Saporin. EML cells treated for 24 hours with 10nM CD117-
saporin followed by an intracellular anti-saporin FITC stain 
c. Annexin V and 7AAD Staining After 24 hours.  
d. BrdU Staining to Assess Cell Cycle Status 24-hours After Treatment.  
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Next, we cultured cKit enriched cells from C57BL/6 mice with saporin, CD117-
saporin, and CD45-saporin for 72 hours and observed that at the 48-hour time point, 
we began to see reduced cell counts in the CD117-saporin and CD45-saporin groups 
which then became significant by the 72 hours timepoint (Figure 4.2a).  
 
Similar to the observation made in EML cells, 24-hour treatment with CD117-saporin 
let to a decrease in cells in S phase (Figure 4.2b). Moreover, across the progenitor, 
LSK, and LT-HSC compartments, we observed well over 50% reduction in op-puro 
incorporation after a 24-hour treatment indicating that saporin treatment inhibits 
protein synthesis in wild-type HSPCs (Figure 4.2c).  
 
Finally, we wanted to know if human HSC exhibit similar reductions upon treatment 
with saporin. CD34 enriched cells from cord blood were treated with saporin, CD117, 
and CD117-saporin for 90 minutes. We have shown that internalization of CD117 
occurs within 90 minutes and we wanted to assess how quickly internalized saporin 
can alter translation. We observed that after 90 minutes, op-puro incorporation was 
reduced by more than 50% in HSCs and progenitor cells (Figure 4.3a). We wanted to 
see whether any functional effects take place with short-term treatment and performed 
CFU assay with treated cells.  After a 7-day culture, we observed an increase in total 
colony output from cells treated with CD117-saporin. A striking increase in erythroid 
colonies was observed possibly indicating an increase in differentiation (Figure 4.3b).  
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FIGURE 4.2. In Vitro Effects of Saporin on WT BM Cells 
a. cKit enriched cells from C57BL/6 mice were plated and treated with saporin, CD117-
saporin, and CD45-saporin. Cell counts at 24, 48, and 72 hours. 
b. cKit enriched cells from C57BL/6 mice were treated with saporin, CD117, and CD117-
saporin and BrdU staining was performed to assess cell cycle status 
c. OP-Puro incorporation assay after 24 hour. Progenitors (Lin- Sca-1- cKit+), LSK (Lin- 
Sca-1+ cKit+), and LT-HSC (Lin- Sca-1+ cKit+  CD34- CD150+)*, p<0.05; **, 
p<0.01; ***, p<0.001 
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FIGURE 4.3. In Vitro Effects of Saporin on Cord Blood HSPCs 
a. OP-Puro incorporation in CD34 enriched cord blood cells following a 90-minute 
saporin, CD117, and CD117-saporin treatment. 
b. 500 CD34 enriched cord blood cells were treated with the immunotoxin for 90-minutes 
and plated in m3434 methylcellulose for 7 days.  
 
 
DISCUSSION 
 
Here we show that the HSCs and progenitors from C57BL/6 mice and cord blood are 
sensitive to saporin treatment.   We demonstrated that progenitor, LSK, and LT-HSC 
populations from mouse bone marrow all have reduced op-puro incorporation after a 
24-hour CD117-saporin treatment. While LT-HSCs already have reduced translation 
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with CD117-saporin treatment may exert a functional effect on the cells. We also 
measured effects of CD117-saporin on EML cells and observed a possible G1 arrest 
suggesting insufficient components for cell cycle to proceed. A previous study 
demonstrated that in saporin treatment of two different glioblastoma cell lines lead to a 
G1 arrest with no increase in apoptosis in one cell line and an increased apoptosis and 
a block in S phase progression in the other (Cimini et al. 2012). These results indicate 
that distinct cellular responses can be induced by saporin in different cells. As we 
proceed forward, mechanism of cell death must be validated across normal and mutant 
mouse and human cells.  
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CHAPTER FIVE 
MATERIALS AND METHODS 
 
Animal Studies 
All animal studies were performed with Memorial Sloan Kettering Cancer Center or 
NYU Langone Medical Center IACUC approval. Wild-type C57BL/6J (CD45.2) mice, 
congenic B6.SJL-Ptprca Pepcb/BoyJ (CD45.1) mice, and CByJ. B6-Tg(UBC-
GFP)30Scha/J mice were purchased from Jackson Laboratories. Hybrid F1 mice were 
generated at MSKCC by crossing CD45.2 C57BL/6J mice with CD45.1 Bs.SJL-
Ptprca Pepcb/BoyJ mice and were used to distinguish donor, competitor, and host cell 
contribution. Vav-cre-Asxl1fl/fl-Tet2 fl/fl and Mx-cre- Asxl1fl/fl-Tet2 fl/fl mice were 
generously provided by Dr. Abdel-Wahab, MSKCC. All mice within each experiment 
were age and sex-matched.  
 
Transplantation 
BM cells for transplantation were harvested by crushing freshly isolated femurs, tibia, 
hips, and spine and were filtered through a 40um strainer. Competitive transplants 
were performed with 20x106 BM mononuclear cells at a 1:1 ratio of CD45.2 Vav-cre-
Asxl1fl/fl-Tet2 fl/fl and CD45.2 UBC-GFP cells. Cells were injected retro-orbitally into 
lethally irradiated (9.5Gy split dose) congenic CD45.1 recipient mice.  
 
Mouse Peripheral Blood Analysis 
Peripheral blood was drawn from the tail-vein and collected in blood collection tubes 
with 0.5M EDTA (Fisher Scientific: 22-040-200). Automated peripheral blood counts 
were obtained using either a HemaVet 950 (Drew Scientific) or ProCyte Dx 
Hematology Analyzer (IDEXX) according to standard manufacturer’s instruction. For 
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flow cytometry quantification of T, B, and myeloid cells, blood samples were treated 
with 2% dextran for 30 minutes at 37C flowed by ACK lysis (ThermoFisher 
Scientific: A10492-01) for 10 minutes at room temperature. Cells were stained with 
the following antibody cocktail in FACS butter for 30 minutes on ice. Ter119-APC 
(eBioscience: 17-5921-82), Gr-1-PE (eBioscience: 12-5931-82), Mac-1-e450 
(eBioscience: 48-0112-82), B220-PE-Cy5 (BioLegend: 103210), and CD3-APC-Cy7 
(eBioscience: 47-0032-82). Donor chimerism analysis were performed using CD45.1-
PE-Cy7 (eBioscience: 25-0453-82), CD45.2-A700 (BioLegend: 109822) and for 
transplants using UBC-GFP cells, chimerism was based on GFP+ events within the 
CD45+ gate. Propidium iodide (BioLegend – 421301) was used to evaluate cell 
viability.  
 
Mouse Bone Marrow Analysis 
Bone marrow aspirates were performed as previously described (Chung, Kim, and 
Abdel-Wahab 2014). Briefly, mice were anesthetized with isoflurane using a 
vaporizer. A 27.5G tuberculin syringe was inserted through the patellar tendon into the 
shaft of the femur and the plunger was pulled back until approximately 5uL were 
collected. For flow cytometry analysis of stem and progenitor cells, cells were stained 
using the following antibody cocktail: Ter119, B220, CD3, CD4, CD8, Gr-1, and 
Mac-1-PE-Cy5 (BioLegend: 116210), Sca-1-Pacific Blue (BioLegend: 122520), 
CD117-APC-Cy7 (105826), CD34-FITC (BioLegend 343604), CD150-PE 
(BioLegend: 115904), and CD16/32-A700 (eBioscience: 56-0161-82). Donor 
chimerism analysis were performed using CD45.1-PE-Cy7 (eBioscience: 25-0453-82), 
CD45.2-A700 (BioLegend: 109822) and for transplants using UBC-GFP cells, 
chimerism was based on GFP+ events within the CD45+ gate.  Propidium iodide 
(BioLegend – 421301) was used to evaluate cell viability. 
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Immunotoxin preparation 
Saporin (Streptavidin-ZAP) was purchased from Advanced Targeting Systems (IT-
27). The number of saporin molecules ranged from 1-2.8 molecules/streptavidin 
depending on the lot. Aliquots of saporin were prepared and stored at -80°C for long-
term use. Biotinylated anti-mouse CD45.2 (clone 104 - 109804), biotinylated anti-
mouse CD117 (clone 2B8 - 105804), biotinylated anti-mouse IgG1, K Isotype control 
antibody (clone MOPC-21 400104) and biotinylated anti-human CD117 (clone 104D2 
– 313208) were purchased from BioLegend. Immunotoxins were prepared by 
combining saporin and antibody at a 1:1 molar ratio and after 10 minutes of incubation 
at room temperature diluted with PBS. In vivo administration of immunotoxin was 
performed by intravenous injections (300µL volume). 
 
Saporin Internalization Assay 
Anti-Saporin FITC labeled (goat polyclonal) antibody was purchased from Advanced 
Targeting Systems (catalog number: FL-02). Aliquots were prepared and stored at -
20°C until use. Cells were first incubated with antibody-saporin conjugate for at least 
90 minutes to allow for internalization at in 5% CO2 at 37°C in culture media. Cells 
were washed with PBS and were treated with fixation/permeabilization solution 
(BDbiosciences - 554714) for 10 minutes at 4°C. Cells were then washed with 1x 
wash buffer provided in the fix/perm kit. Anti-saporin FITC antibody was diluted at 
1:000 in 1x wash buffer and incubated with cells for 30 minutes at room temperature 
in the dark. Internalization of saporin was analyzed by flow cytometry.  
 
Measurement of Antibody Internalization 
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In vitro antibody internalization was assessed as previously described (Schmidt, 
Thurber, and Wittrup 2008). Briefly, EML cells and cKit enriched mouse BM cells in 
respective media were incubated with biotinylated anti-CD117 (clone 2B8) anti-
CD45.2 (clone 104), and IgG1K Isotype (clone MOPC-21) antibody and streptavidin-
AF488 conjugate (Life Technologies). After 24 hours, cells were washed twice with 
FACS buffer (PBS, 2% FBS).  Cells were incubated with and without 0.25mg.mL 
polyclonal anti-AF488 quenching antibody (Life Technologies clone A-11094) and 
AF488 signal was quantified by flow cytometry and allowed for measurement of 
surface and internal fluorescence.  
 
Mouse BM Cell Culture 
BM cells were harvested by crushing freshly isolated femurs, tibia, hips, and spine and 
were filtered through a 40um strainer. For CD117 enrichment, BM cells were 
incubated with CD117 MicroBeads, mouse (Miltenyi Biotec: 130-091-224) for 30 
minutes at 4°C. Cells were passed through LS columns (Miltenyi Biotec: 130-042-
401) on a MACS manual separator. LS column was washed three times with FACS 
buffer and eluted with 5 mL FACS buffer. CD117 enriched cells were plated in 
DMEM-F12 with 10% FBS, 10 ng/µL SCF (Peprotech: 250-03), 10 ng/µL Flt3 ligand 
(Peprotech: 250-31L), 10 ng/µL TPO (Peprotech: 315-14), 10ng/µL IL-3 (Peprotech: 
213-13), and 10 ng/µL IL-6 (Peprotech: 216-16). All cytokines were obtained from 
Peprotech.  
 
Cord Blood Preparation and Culture 
Cord blood units were obtained through the National Cord Blood Program at the New 
York Blood Center. Individual cord blood units were diluted with equal volume PBS, 
2% EDTA buffer and mononuclear cells are subsequently isolated by density gradient 
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centrifugation. 30mL of diluted cord blood were layered onto 15mL Ficoll-Paque 
solution (Fisher 45-001-750 and centrifuged at 1500 rpm for 40 minutes at room 
temperature. Mononuclear cells are carefully collected from the interphase layer 
between the plasma layer and ficoll layer and pooled together. Cells are washed with 
PBS, 2% EDTA buffer and spun for 30 minutes at 1500 rpm at room temperature. For 
CD34 enrichment after density gradient centrifugation, MNCs were incubated with 
CD34 MicroBead Kit, human (Miltenyi Biotec: 130-046-702) for 30 minutes at 4°C. 
Cells were passed through LS columns (Miltenyi Biotec: 130-042-401) on a MACS 
manual separator. LS column was washed three times with FACS buffer and eluted 
with 5 mL FACS buffer. CD34 enriched cord blood cells were plated in StemSpan 
(Stem Cell Technologies: 09600) supplemented with 10% FBS, 20ng/mL TPO 
(Peprotech: 300-18), 20ng/mL IL-3 (Peprotech: 200-03), 20ng/mL G-CSF (Peprotech: 
300-23) and 1% Pen Strep.  
 
Patient Bone Marrow Cell Preparation and Culture 
Patient BM samples were obtained from the Department of Pathology NYU Medical 
Center. BM cells were diluted in FACS buffer and layered onto Ficoll-Paque and spun 
at 1500 rpm for 40 mins at room temperature. Mononuclear cells are carefully 
collected from the interphase layer between the plasma layer and ficoll layer and 
pooled together. Cells are washed with PBS, 2% EDTA buffer and spun for 30 
minutes at 1500 rpm at room temperature. For CD34 enrichment after density gradient 
centrifugation, MNCs were incubated with CD34 MicroBead Kit, human (Miltenyi 
Biotec: 130-046-702) for 30 minutes at 4°C. Cells were passed through LS columns 
(Miltenyi Biotec: 130-042-401) on a MACS manual separator. LS column was washed 
three times with FACS buffer and eluted with 5 mL FACS buffer. CD34 enriched cord 
blood cells were plated in StemSpan (Stem Cell Technologies: 09600) supplemented 
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with 10% FBS, 20ng/mL TPO (Peprotech: 300-18), 20ng/mL IL-3 (Peprotech: 200-
03), 20ng/mL G-CSF (Peprotech: 300-23) and 1% Pen Strep. 
 
EML Cell Culture 
EML cell line, clone 1 was purchased from ATCC (ATCC CRL-11691). Cells were 
cultured in Iscove's modified Dulbecco's medium with 4mM L-glutamine adjusted to 
contain 1.5 g/L sodium bicarbonate (ATCC: ATCC 30-2005) containing 200 ng/ml 
mouse stem cell factor, and 20% FBS. Culture was maintained by replacement of 
media every 2 days to maintain a cell concentration of 1x106 viable cells/mL.  
 
Cell-Cycle and Apoptosis Analysis 
Cell cycle analysis was performed using BD Pharmingen BrdU Flow Kits APC (BD 
Biosciences: 552598). Cells were incubated with 10uL of BrdU solution (1nM BrdU 
in 1x PBS) and incubated for 1 hour followed by staining with cell surface marker 
antibodies for 30 minutes and in the case of staining with mouse CD34 antibody for 
LT-HSCs, cells were stained for 2 hours. Cells were washed and incubated with 
100uL of BD cytofix/cytoperm buffer at 4°C for 10 minutes. Cells were subsequently 
washed with 1x perm/wash buffer and analyzed by flow cytometry. For evaluation of 
apoptosis, the Annexin V–PE apoptosis detection kit (BD Biosciences: 556421) was 
used. Cells were incubated with 5uL of PE Annexin V and 5uL of 7-AAD and 
incubated for 15 minutes at room temperature in the dark. Cells were resuspended in 
1x binding buffer and analyzed by flow cytometry.  
 
CFU-Assay 
Colony assays on CD34 enriched cord blood cells were performed using MethoCult 
H4434 Classic (StemCell: 04434). After cells are isolated, 500 CD34 enriched cells 
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were added to 2mL of H4434 and vigorously vortexed. Using a syringe with a 16-
gauge blunt-end needle, methocult mixture with cells are dispensed into 6-well plates. 
The plate is gently tilted to allow to distribute evenly. Sterile water is added to the 
plate and plate is incubated with 5% CO2 at 37°C for 7-10 days. Colony phenotyping 
was performed using manufacturer’s instructions. Methocult and cells were collected 
and washed twice with 1xPBS and 20,000 cells were plated for secondary plating. The 
remaining cells were stained for flow cytometry analysis.  
 
Cell Viability Assay 
CellTiter-Glo Luminescent Cell Viability Kit (Promega: G7571) was used to 
determine the number of viable cells after immunotoxin treatment. Cells were first 
treated with antibody-saporin conjugates for 72 hours in culture media at 37°C. 
CellTiter-Glo Reagent was added to the cells in equal volume and mixed for two 
minutes on a shaker to induce cell lysis. The plate was incubated for 10 minutes at 
room temperature to stabilize the luminescent signal. Luminescence was recorded on a 
spectrophotometer.  
 
OP-Puro Incorporation Assay (in vitro & in vivo) 
In vitro OP-Puro incorporation assay was performed using either the Click-iT Plus 
OPP Alexa Fluor™ 488 Protein Synthesis Assay Kit (ThermoFisher Scientific: 
C10456) or the Click-iT Plus OPP Alexa Fluor™ 594 Protein Synthesis Assay Kit 
(ThermoFisher Scientific: C10457). Cells were cultured with Dilute Click-iT OPP 
(Component A) at 1:1000 for 30 minutes at 37°C. Cells were fixed and permeabilized 
with 100uL of the BD Fix/perm solution. Cells were washed with 1x wash buffer and 
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incubated with OPP detection solution for 30 minutes at room temperature. Cells were 
washed with Click-iT Reaction Rinse Buffer and subsequently analyzed by flow 
cytometry.  
 
Sucrose Gradients 
10%, 20%, 30%, 40%, 50%, and 60% sucrose solution was prepared in lysis buffer. 
Gradients were prepared by layering each concentration of sucrose followed by 
incubation at -80C for 45 minutes to allow for solidification before adding the next 
layer. Cells of interest were treated with 10mg/ml CHX for 10 minutes at 37°C to 
freeze translating ribosomes in place on the mRNA transcripts. Cell were lysed and on 
top of the sucrose gradient solution and centrifuged at 4°C for 3 hours at 50,000 
rpm.  After centrifugation, 300uL fractions were removed from the top of the 
gradient and placed into pre-chilled microcentrifuge tubes. RNA was isolated using 
RNeasy Mini Kit (Qiagen: 74104) and quantified.  
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CHAPTER SIX 
DISCUSSION & FUTURE DIRECTION 
 
Deregulation of translation has been implicated in many hematologic malignancies 
including MDS. Here we demonstrate in mouse models of MDS and in two MDS 
patient samples, wildtype- and MDS HSCs exhibit decreased translation rates as 
measured by op-puro incorporation. We also show that using an immunotoxin that 
targets the 28S ribosomal subunit, we are able to deplete MDS HSPCs in vivo 
allowing access to open niches for donor HSCs. While it is promising to propose using 
saporin as a conditioning regimen of HSCT for MDS patients or as an adjunct therapy 
to standard care, many questions still remain unanswered.  
How does saporin affect the cell and its cell cycle status? In EML cells, treatment with 
CD117-saporin lead to an increase in the G1 phase and a decrease in S phase 
suggesting a G1 arrest. As a cell progresses through the cell cycle, protein production, 
including production of ribosomal proteins, is highest in the G1 phase making the 
phase most sensitive to translation inhibition. As saporin inhibits translation initiation 
by preventing the 60S subunit from binding to the elongation factor 2 (EEF2), cells 
decide to arrest in G1 instead of committing to the next cell cycle. This arrest in G1 
would also be accompanied by increased doubling time as cells would spend more 
time in the G1 phase and fewer cells would be cycling. With increasing concentration 
of our immunotoxin, we observed a decreasing EML cell viability (Figure 3.1a). 
Whether this is due to cell death or reduced cell growth is unclear. We measured 
apoptosis after a 24-hour treatment and did not observe any significant increase 
however, this does not exclude the possibility of cell death. We need to assess 
apoptotic as well as necrosis pathways at different time points ranging from 24-72 
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hours to allow sufficient time for saporin to exert its effect. Additionally, by 
measuring saporin internalization using a range of saporin concentrations, a 
correlation between amount of toxin can be made to its direct effect.  
Our in vivo study we demonstrated that wild-type GFP and Vav-cre-Asxl1fl/fl-Tet2 fl/fl 
HSCs were depleted upon treatment with both CD117-saporin and CD45-saporin and 
subsequently, donor cells were able to be engrafted. Our data and previously published 
data (Palchaudhuri R et al 2016) show that in vivo depletion takes 6-9 days. What 
happens to HSCs in this time is still unclear. If cells undergo cell death or exhaustion 
during this time, assessing BM in at intermediate timepoints for apoptosis or necrosis 
and functional assays such as CFU and transplantation of phenotypic HSCs may 
provide insight into the process of cell depletion.  
While many studies suggest that defects in ribosome biogenesis exist across MDS 
subtypes, how that affects global translation rates and cell function of HSCs has not 
been validated. Assessment of op-puro incorporation in large cohorts of MDS patient 
samples would allow access to this information and may provide insight into the 
biology of MDS stem cells. However, large cohorts of patient samples are not readily 
available, so an alternative is to study mouse models with ribosomal defects. 
Previously studied Rpl24bst/+ mice have defects in 60S subunit biogenesis. These mice 
exhibit reduced translation in the HSCs and exhibit reduced HSC function (Signer et 
al. 2014). In addition to these mice, the rps19 knockdown, rps6, and rps14 all 
demonstrate that defects in ribosomal proteins are associated with HSC exhaustion or 
reduced HSC function (Choesmel V, Fribourg S, Aguissa-Toure AH, Pinaud N, 
Legrand P and Gleizes PE 2008; McGowan et al. 2011; Schneider et al. 2016). Using 
such mouse models, we would be able to test the efficacy of saporin treatment on cells 
with defects in ribosome biogenesis. Knowing whether the defects in translation make 
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these cells more susceptible to depletion would be important finding to demonstrate 
the specificity by with the Ab-saporin conjugate exerts its effects. As observed in a 
recent study, the effect of CD45-saporin were very specific to the HSC compartment. 
Mice treated with the immunotoxin did not have any significant changes to bulk 
CD45+ cells (Palchaudhuri R et al 2016). A possible reason for this specific depletion 
may be the low translation levels of HSCs compared to other CD45 cells. If true, this 
would allow MDS stem cells to be targeted more so than healthy HSCs as they have 
lower translation rates.   
Translational control is a highly regulated process and aberrations in the process are 
linked with cancers. Ribosomopathies, including MDS, exhibit defects in ribosomal 
proteins and patients have an increased risk of developing a hematologic malignancy. 
On the other hand, increase protein synthesis has also been shown to also promote 
hematologic malignancies, including T cell leukemias (Barna et al. 2008; Hsieh et al. 
2010). Deregulation of translation. While changes in translation leading to a 
malignancy is disease specific, targeting the machinery may serve as a powerful tool 
for malignancies described with either an increase or a decrease in translation.  
A critical question here is whether a defect in ribosome only leads to reduced 
translation or do the defects altered ribosome function leading to the increased risk of 
developing a malignancy? The well understood, housekeeping function of a ribosomal 
protein has been to act as components of the ribosomal structure enabling protein 
synthesis. However, studies have suggested that ribosomal proteins have additional 
physiological functions and defects in these proteins might contribute to disease 
pathogenesis (Ruggero 2013). 
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Saporin has been used as an immunotoxin for many years now and several studies 
have shown its efficacy in targeting malignant stem cells in pre-clinical studies 
(Ferreras et al. 2011; Polito 2004).  Several clinical trials have also been conducted 
with saporin containing immunotoxins and have been well tolerated. The first trial 
used a CD30-saporin conjugate in patients with advanced refractory Hodgkin’s 
disease. Side effects including fever, myalgias, thrombocytopenia, and transient liver 
damage were observed in 70% of patients (Falini et al. 1992; Pasqualucci et al. 1995). 
A second trial using bispecific F(ab’) antibodies with saporin in lymphoma patients 
and only mild fever, weakness, and myalgia for 1-2 days after the treatment were 
described (French et al. 1995, 1996).  
The use of an immunotoxin such as CD117-saporin has some advantages compared to 
other therapies. Unlike treatment with lenalidomide or myeloablative conditioning for 
HSCT, the immunotoxin activity is not limited dividing cell. Both dividing and 
quiescent cells have been demonstrated to be affected by the saporin treatment by 
showing reduction in translation. Moreover, an immunotoxin can only exert its effects 
on the targeted cells based on the antibody making it a non-ablative method of 
eliminating disease-initiating cells.   
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